FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2974587115> ?p ?o ?g. }

• W2974587115 endingPage "3910" @default.
• W2974587115 startingPage "3910" @default.
• W2974587115 abstract "Background: Although virtually all patients (pts) with AML or MDS harbor at least one somatic mutation, a minority of pts possess genetic mutations considered directly targetable by a drug. Moreover, in pts with multiple gene mutations, single-gene/single-drug matching often produces conflicting drug recommendations. This lack of clinically relevant mutation-targeted therapy represents an unmet need in treating AML and MDS, and is a major limitation in personalized medicine. We hypothesized that genomic mutations from pts with AML or MDS could be used to generate pt-specific protein network maps for use in digital drug screening (DDS) even in cases when the gene mutations per se are not directly actionable. This would dramatically increase the percent of pts with actionable findings. Our primary goal was to establish a genomics and computational biology workflow that identified disease-relevant treatment options for every pt. Methods: We prospectively enrolled AML and MDS pts and collected bone marrow (BM), peripheral blood and clinical data relevant to their diagnosis and treatment. BM specimens were examined by conventional cytogenetics (Giemsa), whole exome sequencing (WES, Agilent), and copy number variation (CNV). Directly actionable mutations were defined as IDH1/2, JAK2, NRAS, KRAS, FLT3, TET2 or del(5q), based on currently available drugs that directly act on these mutations. Genomic data from each pt were used as inputs into a computational biology modeling (CBM) software (Cellworks Group), that generated pt-specific protein network maps based on software written from PubMed references and other online databases. DDS was conducted by mathematically quantifying drug effects on a cell growth score (CGS), which is a composite of modeled cell proliferation, viability and apoptosis. 77 drug combinations, comprised of 10 standard of care (SOC) and 16 non-SOC drugs were digitally screened on each pt9s case to identify drug or drug combinations with significant reductions in CGS. Evaluation for drug-drug synergy was calculated by coefficient of drug interaction (CDI) and the extent to which each drug reduced the CGS. Results: 80 pts with either AML (n=41, 51%) or MDS (n=31, 39%), or myeloproliferative neoplasms (n=8, 10%) were successfully analyzed by the genomics and computational biology analysis plan. 23/80 (29%) were treatment-naive, while 58/80 (71%) were treatment-refractory. The median age was 65 years (range 36-90). While 28/80 (34%) pts had a directly actionable mutation, 53/80 (66%) patients did not. Disease-relevant biomarkers were identified for all (100%) of the pts using the CBM technology, involving pathways related to kinase activity (BTK, MAPK3, SRC, AURKA/B, AKT, mTOR, etc.) and transcription factors (TP53, MYC_MAX, CTNNB1, NFkB1, RUNX3, STAT3, etc.). DDS identified 77 unique drug combinations with potential therapeutic activity in these 81 patients, where cytarabine + dexamethasone (n=10), cytarabine + ruxolitinib (n=8), cytarabine + everolimus (n=6) were the most commonly identified combinations. A majority of pts (63/80, 79%) were predicted to respond to a combination of SOC + non-SOC, while 18/80 (21%) patient9s cases were predicted to respond to a combination of non-SOC + non-SOC. In addition to selecting therapeutic regimens, computational modeling identified 9 pt cases whose simulated drug combinations resulted in synergistic activity, more frequently including cytarabine + ruxolitinib or cytarabine + dexamethasone. Conclusions: In contrast to a widely used practices of next generation sequencing techniques to identify single-gene/single-drug matching, this strategy of using a protein networking mapping and DDS identified therapeutic options for all pts with AML or MDS, even when there was no directly actionable mutation. In clinical situations of no established standard of care, such as refractory AML or MDS, the use of computational modeling and digital drug simulations may increase therapeutic options. CBM is currently being validated in a prospective clinical trial (NCT02435550). These results serve as the basis for a new, non-basketized clinical trial testing the effectiveness of computer-informed treatment based on the pt9s malignant mutanome. Disclosures Norkin: Celgene: Honoraria, Research Funding. Vasista: Cellworks Research India: Employment. Basu: Cellworks: Employment. Usmani: Cellworks: Employment. Roy: Cellworks: Employment. Lala: Cellworks: Employment. Radhakrishnan: Cellworks: Employment. Kumar: Cellworks: Employment. Rajagopalan: Cellworks: Employment. Abbasi: Cellworks Group Inc.: Employment. Vali: Cellworks Group Inc.: Employment. Cogle: Celgene: Other: Membership on Steering Committee for Connect MDS/AML Registry." @default.
• W2974587115 created "2019-09-26" @default.
• W2974587115 creator A5001898266 @default.
• W2974587115 creator A5008762363 @default.
• W2974587115 creator A5020415674 @default.
• W2974587115 creator A5023628069 @default.
• W2974587115 creator A5025323115 @default.
• W2974587115 creator A5027276733 @default.
• W2974587115 creator A5027878763 @default.
• W2974587115 creator A5028647693 @default.
• W2974587115 creator A5037089886 @default.
• W2974587115 creator A5038067131 @default.
• W2974587115 creator A5042492175 @default.
• W2974587115 creator A5044011484 @default.
• W2974587115 creator A5045260141 @default.
• W2974587115 creator A5049745844 @default.
• W2974587115 creator A5052564856 @default.
• W2974587115 creator A5053557310 @default.
• W2974587115 creator A5062184019 @default.
• W2974587115 creator A5065927929 @default.
• W2974587115 creator A5066917259 @default.
• W2974587115 creator A5071237407 @default.
• W2974587115 creator A5072283393 @default.
• W2974587115 creator A5078899007 @default.
• W2974587115 creator A5086399567 @default.
• W2974587115 creator A5090486615 @default.
• W2974587115 date "2017-12-07" @default.
• W2974587115 modified "2023-09-28" @default.
• W2974587115 title "Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)" @default.
• W2974587115 doi "https://doi.org/10.1182/blood.v130.suppl_1.3910.3910" @default.
• W2974587115 hasPublicationYear "2017" @default.
• W2974587115 type Work @default.
• W2974587115 sameAs 2974587115 @default.
• W2974587115 citedByCount "0" @default.
• W2974587115 crossrefType "journal-article" @default.
• W2974587115 hasAuthorship W2974587115A5001898266 @default.
• W2974587115 hasAuthorship W2974587115A5008762363 @default.
• W2974587115 hasAuthorship W2974587115A5020415674 @default.
• W2974587115 hasAuthorship W2974587115A5023628069 @default.
• W2974587115 hasAuthorship W2974587115A5025323115 @default.
• W2974587115 hasAuthorship W2974587115A5027276733 @default.
• W2974587115 hasAuthorship W2974587115A5027878763 @default.
• W2974587115 hasAuthorship W2974587115A5028647693 @default.
• W2974587115 hasAuthorship W2974587115A5037089886 @default.
• W2974587115 hasAuthorship W2974587115A5038067131 @default.
• W2974587115 hasAuthorship W2974587115A5042492175 @default.
• W2974587115 hasAuthorship W2974587115A5044011484 @default.
• W2974587115 hasAuthorship W2974587115A5045260141 @default.
• W2974587115 hasAuthorship W2974587115A5049745844 @default.
• W2974587115 hasAuthorship W2974587115A5052564856 @default.
• W2974587115 hasAuthorship W2974587115A5053557310 @default.
• W2974587115 hasAuthorship W2974587115A5062184019 @default.
• W2974587115 hasAuthorship W2974587115A5065927929 @default.
• W2974587115 hasAuthorship W2974587115A5066917259 @default.
• W2974587115 hasAuthorship W2974587115A5071237407 @default.
• W2974587115 hasAuthorship W2974587115A5072283393 @default.
• W2974587115 hasAuthorship W2974587115A5078899007 @default.
• W2974587115 hasAuthorship W2974587115A5086399567 @default.
• W2974587115 hasAuthorship W2974587115A5090486615 @default.
• W2974587115 hasConcept C104317684 @default.
• W2974587115 hasConcept C10590036 @default.
• W2974587115 hasConcept C143998085 @default.
• W2974587115 hasConcept C16671776 @default.
• W2974587115 hasConcept C21790070 @default.
• W2974587115 hasConcept C2781187634 @default.
• W2974587115 hasConcept C2994225774 @default.
• W2974587115 hasConcept C32220436 @default.
• W2974587115 hasConcept C501734568 @default.
• W2974587115 hasConcept C54355233 @default.
• W2974587115 hasConcept C60644358 @default.
• W2974587115 hasConcept C70721500 @default.
• W2974587115 hasConcept C71924100 @default.
• W2974587115 hasConcept C86803240 @default.
• W2974587115 hasConceptScore W2974587115C104317684 @default.
• W2974587115 hasConceptScore W2974587115C10590036 @default.
• W2974587115 hasConceptScore W2974587115C143998085 @default.
• W2974587115 hasConceptScore W2974587115C16671776 @default.
• W2974587115 hasConceptScore W2974587115C21790070 @default.
• W2974587115 hasConceptScore W2974587115C2781187634 @default.
• W2974587115 hasConceptScore W2974587115C2994225774 @default.
• W2974587115 hasConceptScore W2974587115C32220436 @default.
• W2974587115 hasConceptScore W2974587115C501734568 @default.
• W2974587115 hasConceptScore W2974587115C54355233 @default.
• W2974587115 hasConceptScore W2974587115C60644358 @default.
• W2974587115 hasConceptScore W2974587115C70721500 @default.
• W2974587115 hasConceptScore W2974587115C71924100 @default.
• W2974587115 hasConceptScore W2974587115C86803240 @default.
• W2974587115 hasLocation W29745871151 @default.
• W2974587115 hasOpenAccess W2974587115 @default.
• W2974587115 hasPrimaryLocation W29745871151 @default.
• W2974587115 hasRelatedWork W1539455863 @default.
• W2974587115 hasRelatedWork W2037758905 @default.
• W2974587115 hasRelatedWork W2082318306 @default.
• W2974587115 hasRelatedWork W2292061167 @default.
• W2974587115 hasRelatedWork W2547746944 @default.
• W2974587115 hasRelatedWork W2618317511 @default.
• W2974587115 hasRelatedWork W2790449611 @default.
• W2974587115 hasRelatedWork W2946049250 @default.

• next